Determination of pCrkL level in chronic myeloid leukaemia cells using flow cytometry
| Authors | |
|---|---|
| Year of publication | 2010 |
| Type | Article in Proceedings |
| Conference | Advances in Molecular and Cancer Biology, 2010 |
| MU Faculty or unit | |
| Citation | |
| Field | Genetics and molecular biology |
| Keywords | CML; imatinib; CD34+; pCrkL; flow cytometry |
| Description | Imatinib is a tyrosine kinase inhibitor nowadays used as a first line therapy for newly diagnosed chronic myeloid leukaemia (CML) patients. However, some of the patients relapse after initially good response. Therefore, reliable methods for predicting of the imatinib treatment response are sought. In our research we determine the level of phosphorylated CrkL protein, known as a substrate of Bcr-Abl, by flow cytometry. Its potential predictive value as a marker of imatinib treatment response will be assessed in the monuclear cells or CD34+ cells of peripheral blood samples of new CML patients. |
| Related projects: |